Exposure of the cryptic de-adhesive site FNIII14 in fibronectin molecule and its binding to membrane-type eEF1A induce migration and invasion of cancer cells via β1-integrin inactivation.

Integrin de-adhesion eukaryotic translation elongation factor 1A extracellular matrix fibronectin metastasis

Journal

American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944

Informations de publication

Date de publication:
2020
Historique:
received: 23 08 2020
accepted: 13 10 2020
entrez: 9 12 2020
pubmed: 10 12 2020
medline: 10 12 2020
Statut: epublish

Résumé

Cell migration is a highly coordinated process that involves not only integrin-mediated adhesion but also de-adhesion. We previously found that a cryptic de-adhesive site within fibronectin molecule, termed FNIII14, weakens cell adhesion to the extracellular matrix by inactivating β1-integrins. Surprisingly, eukaryotic translation elongation factor-1A (eEF1A), an essential factor during protein biosynthesis, was identified as a membrane receptor that mediates the de-adhesive effect of FNIII14. Here, we demonstrate that FNIII14-mediated de-adhesion causes enhanced migration and invasion in two types of highly invasive/metastatic cancer cells, resulting in the initiation of metastasis. Both

Identifiants

pubmed: 33294281
pmc: PMC7716165

Types de publication

Journal Article

Langues

eng

Pagination

3990-4004

Informations de copyright

AJCR Copyright © 2020.

Déclaration de conflit d'intérêts

None.

Références

Methods Mol Biol. 2012;878:121-35
pubmed: 22674130
Nat Rev Cancer. 2003 May;3(5):362-74
pubmed: 12724734
Mol Cancer Ther. 2019 Sep;18(9):1649-1658
pubmed: 31189613
Pathol Int. 2002 Apr;52(4):255-64
pubmed: 12031080
Clin Cancer Res. 2002 Jul;8(7):2455-62
pubmed: 12114453
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
Cell. 1996 Feb 9;84(3):359-69
pubmed: 8608589
J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):944-5
pubmed: 12810785
Int J Mol Med. 2011 Aug;28(2):181-6
pubmed: 21617848
J Biol Chem. 2012 Dec 21;287(52):43424-37
pubmed: 23118220
Semin Cancer Biol. 2015 Dec;35 Suppl:S244-S275
pubmed: 25865774
Nat Rev Drug Discov. 2014 Dec;13(12):904-27
pubmed: 25376097
J Invest Dermatol. 2005 Mar;124(3):633-7
pubmed: 15737205
Oncotarget. 2019 Aug 13;10(48):4960-4972
pubmed: 31452837
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
J Cell Biol. 1981 Jul;90(1):187-200
pubmed: 7195906
Microsc Res Tech. 1998 Dec 1;43(5):420-32
pubmed: 9858339
iScience. 2018 Nov 30;9:502-512
pubmed: 30472533
J Biol Chem. 2012 May 4;287(19):16037-46
pubmed: 22399298
Am J Pathol. 2000 May;156(5):1489-98
pubmed: 10793060
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195598
Tumour Biol. 2006;27(1):17-26
pubmed: 16340246
Clin Cancer Res. 2007 Oct 1;13(19):5889-96
pubmed: 17908984
Int J Mol Sci. 2019 Jun 28;20(13):
pubmed: 31261783
Breast Cancer Res Treat. 2014 Nov;148(2):269-77
pubmed: 25292421
J Cell Sci. 2011 Feb 1;124(Pt 3):369-83
pubmed: 21224397
Blood. 2012 Jan 5;119(1):26-33
pubmed: 21921044
Cancer Res. 1986 Jan;46(1):1-7
pubmed: 2998604
Nat Rev Cancer. 2002 Feb;2(2):91-100
pubmed: 12635172
Biochemistry. 2000 Jun 20;39(24):7138-44
pubmed: 10852711
Biosci Biotechnol Biochem. 2002 Jan;66(1):1-21
pubmed: 11866090
J Cell Sci. 2005 Sep 1;118(Pt 17):3829-38
pubmed: 16129881
Anticancer Res. 2014 Feb;34(2):651-8
pubmed: 24510995
Ann N Y Acad Sci. 2009 Aug;1171:87-93
pubmed: 19723040
Clin Exp Metastasis. 2002;19(3):233-46
pubmed: 12067204
Biochem Biophys Res Commun. 1996 Mar 18;220(2):394-8
pubmed: 8645316
Nat Rev Cancer. 2010 Jan;10(1):9-22
pubmed: 20029421
Adv Clin Chem. 2004;38:87-110
pubmed: 15521189
Invest Ophthalmol Vis Sci. 2011 Jul 25;52(8):5529-35
pubmed: 21519029
Kidney Int. 1997 May;51(5):1454-62
pubmed: 9150458
Eur J Biochem. 1993 Aug 1;215(3):549-54
pubmed: 8354261
J Cancer Res Clin Oncol. 2015 Jul;141(7):1265-75
pubmed: 25601347
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4697-701
pubmed: 18689700
BMC Cancer. 2005 Sep 12;5:113
pubmed: 16156888
Int J Mol Sci. 2017 Jan 17;18(1):
pubmed: 28106752
J Clin Invest. 2001 Apr;107(7):785-90
pubmed: 11285293
Cancer Res. 2013 Oct 15;73(20):6099-105
pubmed: 24097826
Biol Pharm Bull. 2007 May;30(5):891-7
pubmed: 17473431
Nat Genet. 2002 Jul;31(3):301-5
pubmed: 12053177

Auteurs

Keisuke Itagaki (K)

Department of Molecular Pathophysiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Manabu Sasada (M)

Department of Molecular Pathophysiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Satoru Miyazaki (S)

Department of Medical and Life Science, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Takuya Iyoda (T)

Department of Molecular Pathophysiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Takahiro Imaizumi (T)

Department of Molecular Pathophysiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Makoto Haga (M)

Department of Molecular Pathophysiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Akira Kuga (A)

Department of Molecular Pathophysiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Hiroki Inomata (H)

Department of Molecular Pathophysiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Yosuke Kondo (Y)

Department of Medical and Life Science, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Satoshi Osada (S)

Department of Biochemistry, Faculty of Science and Engineering, Saga University 1 Honjo-machi, Saga 840-8502, Japan.

Hiroaki Kodama (H)

Department of Biochemistry, Faculty of Science and Engineering, Saga University 1 Honjo-machi, Saga 840-8502, Japan.

Yoshikazu Higami (Y)

Department of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Fumio Fukai (F)

Department of Molecular Pathophysiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

Classifications MeSH